Media Center

At PATH, our global health experts are developing partnerships, new devices, and solutions to the world's most pressing health needs. Contact us to speak with one of PATH's experts today.

Contact Us

Director of Global Strategic Communications:
Lindsay Bosslet, MPH

Phone: 206.285.3500

Fax: 206.285.6619

Email: media@path.org

Recent Press Coverage

  1. Africa Centres for Disease Control and Prevention, the Clinton Health Access Initiative, and PATH examined the current and planned vaccine manufacturing capacity in Africa to better understand how to develop a sustainable vaccine manufacturing ecosystem.
    Published: October 2023
  2. An analysis of the RTS,S malaria vaccine in Africa shows it decreased toddler deaths by 13 percent. PATH’s John Bawa speaks with Science about these remarkable results.
    Published: October 2023
  3. From health data exchanges to a telemedicine task force, PATH’s Varun Kaul and co-author Anirban Sarma break down eight approaches that the G20 could take to strengthen digital health across its member states.
    Published: October 2023
  4. The Africa Centres for Disease Control and Prevention, the Clinton Health Access Initiative, and PATH examined the current and planned vaccine manufacturing capacity in Africa.
    Published: October 2023

We develop evidence-based expertise and resources

Our global team leverages data and evidence to develop resources and innovations that bring good health to more people.

Explore our evidence

Join the latest discussions on health equity.

We partner with the public and private sector, government, and academia from around the world to share insightful conversations on the latest topics affecting health equity.

Explore PATH events

PATH Newsroom

948 Item s
948 Item s
    Date
    From
    To
  1. Published: February 2024
    Press Release
  2. Published: February 2024
    Press Release
  3. Published: February 2024
    Statement
  4. The NDV-HXP-S COVID-19 vaccine produced by Thailand’s Government Pharmaceutical Organization (GPO) has the potential to be an affordable option that advances vaccine supply sustainability and pandemic preparedness.
    Published: January 2024
    Statement
  5. Emergency use of nOPV2 has protected millions against polio. Prequalification will ensure broad, long-term accessibility.
    Published: January 2024
    Announcement